33 results about "CD23" patented technology

Disclosed herein are compositions and methods of use comprising combinations of anti-CD22 antibodies with a therapeutic agent. The therapeutic agent may be attached to the anti-CD22 antibody or may be separately administered, either before, simultaneously with or after the anti-CD22 antibody. In preferred embodiments, the therapeutic agent is an antibody or fragment thereof that binds to an antigen different from CD22, such as CD19, CD20, CD21, CD22, CD23, CD37, CD40, CD40L, CD52, CD80 and HLA-DR. However, the therapeutic agent may an immunomodulator, a cytokine, a toxin or other therapeutic agent known in the art. More preferably, the anti-CD22 antibody is part of a DNL complex, such as a hexavalent DNL complex. Most preferably, combination therapy with the anti-CD22 antibody or fragment and the therapeutic agent is more effective than the antibody alone, the therapeutic agent alone, or the combination of anti-CD22 antibody and therapeutic agent that are not conjugated to each other. Administration of the anti-CD22 antibody and therapeutic agent induces apoptosis and cell death of target cells in diseases such as B-cell lymphomas or leukemias, autoimmune disease or immune dysfunction disease.

A combination antibody therapy for treating B cell malignancies using an immunoregulatory antibody, especially an anti-B7, anti-CD23, or anti-CD40L antibody and a B cell depleting antibody, especially anti-CD19, anti-CD20, anti-CD22 or anti-CD37 antibody is provided. Preferably, the combination therapy will comprise anti-B7 and anti-CD20 antibody administration.

Methods and kits for the treatment of neoplastic disorders comprising the use of a CD23 antagonist are provided. The CD23 antagonist may be used alone or in combination with chemotherapeutic agents. In particularly preferred embodiments the CD23 antagonists may be used to treat B cell chronic lymphocytic leukemia (B-CLL).

Disclosed are compositions comprising an Fc portion of IgE coupled to an agent. For example, disclosed are compositions comprising an Fc portion of IgE coupled to an antigen or immunotherapeutic. These compositions can be used as a vaccine or an immunotherapeutic. Thus, these compositions can modulate the immune system by both increasing and decreasing the immune response. The Fc portion of IgE can bind to CD23 and transport the antigen or immunotherapeutic across airway epithelial cells. Disclosed are methods of treating airway inflammation with compositions comprising an Fc portion of IgE coupled to an antigen or immunotherapeutic.

The present invention provides compositions and methods for the treatment of asthma. The compositions can be, for example, siRNA directed to CD23. The invention also provides a method of treating asthma with a formulation for in vivo delivery of a CD23 siRNA to inhibit IgE binding in a patient.

The invention provides an agent comprising: (i) a T cell antigen, and (ii) a binding partner for any of CD22, CD23, CD30, CD74, CD70, CD43, CD44, CD47, CD54, CD58, CD62L, CD95, HLA-DR, CD59, CD55, wherein, following binding of the agent to a cell that expresses any of CD22, CD23, CD30, CD74, CD70, CD43, CD44, CD47, CD54, CD58, CD62L, CD95, HLA-DR, CD59, CD55, the agent is internalised and the T cell antigen is presented on the surface of the cell in a form that can be recognised by a T cell.

The embodiments of the present invention provide a bispecific chimeric antigen receptor, consisting of a signal peptide, two specific antigen-binding fragments, an extracellular spacer region, a transmembrane region, an intracellular co-stimulatory signaling domain, the first antigen that is recognized and bound by the specific antigen-binding fragments is a member selected from the group consisting of CD19, CD20, CD22, CD33, CD269, CD138, CD79a, CD79b, CD23, ROR1, CD30, B cell surface antibody light chain, CD44, CD123, Lewis Y, CD7 and CD46; the second antigen that is recognized and bound by the specific antigen-binding fragments is CD38, the two specific antigen-binding fragments is linked by a linker peptide, the bispecific chimeric antigen receptor can recognize respectively two kinds of tumor-associated antigens by constructing low affinity chimeric antigen receptors and high affinity chimeric antigen receptors and have very strong specificity. In addition, the embodiments of the present invention also provide a use of the bispecific chimeric antigen receptor in the treatment of tumors.

The presently disclosed subject matter discloses isolated ADAM 10 modulating peptides and related compounds useful for studying the biological functions of ADAM 10 and for the treatment of diseases such as cancer, neurological disorders, asthma, and allergic responses, and disorders characterized at least in part by the presence of one or more of inflammation, excess cell proliferation, angiogenesis, and excess soluble CD23. In one aspect, the presently disclosed subject matter provides isolated mouse and human ADAM 10 prodomain comprising the sequence set forth in SEQ ID NOs 1-8, or a sequence having at least 95% homology to any of SEQ ID NOs 1-8 and having the functionality of modulating ADAM 10 activity.

Methods for inhibiting IgE production in a human subject using anti-CD23 antibodies.

The present invention relates to the treatment of autoimmune diseases with a combination of an immunomodulatory antibody (such as an anti-B7.1 or anti-B7.2 or anti-CD40L antibody) and at least one B-cell antibody (such as CD19, CD20, CD22, CD23 or CD37), wherein These antibodies may be administered alone or in combination and in either order for extended periods of time.

The invention discloses a Fab fragment of a human anti-human CD23 antibody, a pharmaceutical composition and application of the Fab fragment. The Fab fragment comprises a light chain V region and a heavy chain V region, the amino acid sequence of the light chain V region is shown as SEQ ID NO.1, and the amino acid sequence of the heavy chain V region is shown as SEQ ID NO.2. The Fab fragment can specifically recognize human CD23, has relatively high affinity, and can be used for regulating and controlling the activity of the CD23, so that the adhesion of mediated cells is controlled, the release of IgE and histamine is regulated, and the apoptosis of B cells can be avoided and the growth of bone marrow cells can be regulated by regulating and controlling the activity of the CD23. The Fab fragment of the human anti-human CD23 antibody can be used for preparing medicines for treating lymph-related diseases.